β-羟丁酸在炎症性[18F]-FDG PET检查中识别心肌葡萄糖摄取抑制的效用
研究纳入220例患者共256次[18F]-FDG PET检查,评估血清β-羟丁酸(BHB)能否识别左心室心肌摄取抑制。左心室抑制充分者BHB中位数0.6 mmol/l,显著高于未抑制者的0.2 mmol/l(p < 0.001)。验证队列中BHB ≥ 0.335 mmol/l识别充分抑制的敏感度84.90%、特异度92.60%。
要点
- 左心室抑制充分者BHB中位数0.6 mmol/l,高于未抑制者的0.2 mmol/l(p < 0.001)。
- 验证队列中BHB ≥ 0.335 mmol/l识别充分左心室抑制的敏感度84.90%、特异度92.60%。
- BHB ≥ 0.41 mmol/l者全部(100%)心肌抑制充分,BHB ≤ 0.20 mmol/l者为29.63%。
核心结论
- 血清BHB水平可在床旁用于识别接受[18F]-FDG PET心脏炎症/感染性检查患者的左心室充分抑制。
研究设计与样本
- 连续纳入接受[18F]-FDG PET显像的患者,所有患者在显像当日注射[18F]-FDG前测量血清BHB水平。
- 心肌[18F]-FDG抑制定义为心肌壁SUV摄取值低于血池。
- BHB最佳阈值基于随机30%样本(推导队列)的ROC分析确定,并在其余70%样本(验证队列)中检验。
主要发现
- 共纳入220例患者的256幅图像。
- 左心室抑制充分者BHB中位数(IQR)为0.6(0.3-0.8)mmol/l,未抑制者为0.2(0.2-0.3)mmol/l,p < 0.001。
- 验证队列中BHB ≥ 0.335 mmol/l识别充分左心室抑制的敏感度84.90%、特异度92.60%。
- BHB ≥ 0.41 mmol/l的患者全部(100%)心肌抑制充分,BHB ≤ 0.20 mmol/l的患者中29.63%抑制充分。
关键数值与推荐
- 心肌[18F]-FDG抑制定义为心肌壁SUV摄取值低于血池。
- 验证队列中BHB ≥ 0.335 mmol/l识别充分左心室抑制的敏感度84.90%、特异度92.60%。
临床怎么用
- 血清BHB水平可在床旁用于识别接受[18F]-FDG PET心脏炎症/感染性检查患者的左心室充分抑制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated whether serum beta-hydroxybutyrate (BHB) can identify adequate suppression of the left ventricle (LV) among patients undergoing [18F]-fluorodeoxyglucose positron emission tomography ([18F]-FDG PET) for cardiac inflammatory/infectious studies. METHODS: Consecutive patients who underwent [18F]-FDG PET imaging were included. Serum BHB levels were measured in all patients on the day of imaging prior to injecting [18F]-FDG. Myocardial [18F]-FDG suppression was defined if [18F]-FDG uptake in the walls of myocardium, measured using standardized uptake values (SUV), was lower than the blood pool. The optimal threshold of BHB to identify myocardial suppression was based on receiver operating characteristics (ROC) in a random 30% sample of the study population (derivation cohort) and tested in the remaining 70% of sample (validation cohort). RESULTS: A total of 256 images from 220 patients were included. Patients with sufficient LV suppression had significantly higher BHB levels compared to those with non-suppressed myocardium (median (IQR) BHB 0.6 (0.3-0.8) vs. 0.2 (0.2-0.3) mmol/l, p < 0.001, respectively). BHB level ≥ 0.335 mmol/l had a sensitivity of 84.90% and a specificity of 92.60% to identify adequate LV suppression in the validation cohort. All patients (100%) with BHB ≥ 0.41 mmol/l had adequate myocardial suppression compared to 29.63% of patients with BHB ≤ 0.20 mmol/l. CONCLUSION: Serum BHB level can be used at the point of care to identify sufficient LV suppression in patients undergoing [18F]-FDG PET cardiac inflammatory/infectious studies. Central illustration (image to the right) shows representative cases of patient images and BHB and, in the image to the left, shows the sensitivity and specificity to identify left myocardial suppression using BHB in validation group.
引用
- Alfawara MS, Ahmed AI, Saad JM, et al. The utility of beta-hydroxybutyrate in detecting myocardial glucose uptake suppression in patients undergoing inflammatory [18F]-FDG PET studies. Eur J Nucl Med Mol Imaging. 2022. PMID: 36474124. doi:10.1007/s00259-022-06062-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。